RTSN

10.51019.22%
PS

Paul Sweetnam

Co-Founder, Chief Scientific Officer & Secretary

Dr. Paul Sweetnam, Ph.D., is Co-Founder, Chief Scientific Officer and Secretary of Response Pharmaceuticals Inc. Dr. Sweetnam is Co-Founder & CSO of Retension Pharmaceuticals, Inc. from July 2023. Dr. Sweetnam is the founder of CellBridge, LLC. He is co-founder, CSO and director of Restor. Dr. Sweetnam served as Chief Technology Officer of Nano Terra Life Sciences. He serves as a manager of Redux. Dr. Sweetnam served as Member of Scientific Advisory Board at Predictive Oncology Inc. (formerly known as Precision Therapeutics Inc.). Dr. Sweetnam served as a Chief Scientific Officer of Surface Logix Inc. Prior to joining Surface Logix in August 2001, he served as a Vice President of Research Technologies at Bayer Pharmaceuticals. While at Bayer, his key focus areas were bioinformatics, genomics, protein biosciences, assay development, HTS, in-vivo and in-vitro pharmacokinetics, toxicology and comparative medicine. He was also responsible for the identification, evaluation and integration of external opportunities in the areas of pharmacology, high throughput screening, molecular biology, protein biosciences and chemical diversity. During his tenure at Bayer. Dr. Sweetnam helped oversee the delivery of nine candidate molecules to development. Prior to Bayer, he was employed by Pfizer Phptimizing potential and/or novel drug discovery targets. His positions have included Vice President of Research Technologies at Bayer Healthcare and Chief Scientific Officer at Surface Logix, Inc.He served as Vice President of the Pharmaceutical Division at Bayer Corporation. He served as Scientific Director of Caliper Discovery Alliances & Services. He serves as the Chair of the Scientific Advisory Board at Adenios, Inc. He was a Member of Medical Advisory Board of Skyline Medical Inc. since September 2016. He served as an Assistant Professor in the Department of Neurosurgery for the University of Miami School of Medicine. He is employee at Pfizer Inc. A classically trained neurobiologist with a strong background in biochemical and cellular biology as well as in vivo pharmacology. Dr. Sweetnam has received numerous fellowships and awards and has published more than 35 papers and 75 abstracts. Dr. Sweetnam received a B.S. in biology from the University of Maine, earned his Ph.D. in neurobiology at Georgetown University, was a Postdoctoral Fellow in neuropharmacology in the Department of Psychiatry at the Yale University School of Medicine.

Positions